Showing results (21-30 of 46) with videos related to

Sort By:
Pageof 5
European Journal of Cancer & Clinical Oncology|September 1, 1987
A mathematical model of the development of drug resistance to cancer chemotherapyB G Birkhead, E M Rankin, S Gallivan, et al.
The Journal of Antimicrobial Chemotherapy|October 1, 1984
Observations on the toxicity of the combination of gentamicin and mezlocillin in the treatment of patients with acute leukaemiaE M Rankin, D M Jones, F G Lawston, et al.
British Journal of Cancer|September 13, 2007
First-into-man phase I and pharmacokinetic study of XR5944.14, a novel agent with a unique mechanism of actionW Verborg, H Thomas, D Bissett, et al.
British Journal of Cancer|July 1, 1990
A pilot study of quinidine and epirubicin in the treatment of advanced breast cancerR D Jones, D J Kerr, A N Harnett, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
Reconstitution of recombinant interleukin-2 (rIL-2): a comparative study of various rIL-2 muteinsL T Vlasveld, J H Beijnen, J J Sein, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 1994
Phase II study of intermittent continuous infusion of low-dose recombinant interleukin-2 in advanced melanoma and renal cell cancerL T Vlasveld, S Horenblas, A Hekman, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1989
Phase I clinical and pharmacokinetic study of LY 195448J Cassidy, C Lewis, L Adams, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|April 1, 1994
Catheter-related complications in 52 patients treated with continuous infusion of low dose recombinant interleukin-2 via an implanted central venous catheterL T Vlasveld, S Rodenhuis, E J Rutgers, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1993
Phase I clinical study of LL-D49194 alpha 1 with retrospective pharmacokinetic investigations in mice and humans. The EORTC ECTGJ Cassidy, M A Graham, W Ten Bokkel Huinink, et al.
British Journal of Cancer|November 1, 1988
Pharmacokinetics and anti-emetic efficacy of BRL43694, a new selective 5HT-3 antagonistJ Cassidy, V Raina, C Lewis, et al.
Pageof 5